已收盘 12-19 16:00:00 美东时间
+0.160
+0.12%
今日重点评级关注:巴克莱:维持Iovance Biotherapeutics"超配"评级,目标价从9美元升至10美元;摩根大通:上调Recursion Pharmaceuticals评级至"超配",目标价从10美元升至11美元
12-18 10:54
Morgan Stanley analyst Toni Kaplan maintains Thomson Reuters (NASDAQ:TRI) with a Equal-Weight and lowers the price target from $172 to $165.
12-17 23:44
The New York Times (NYT) said Thursday it is suing the Pentagon after it implemented a new policy on U.S. military reporting, which the newspaper alleges violates its journalists' First and Fifth Amen...
12-04 23:38
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从3美元升至9美元;HC Wainwright & Co.:上调CervoMed评级至"买入",目标价从11美元升至25美元
11-06 09:55
Enabling professionals to delegate complex, multi-step tasks and transform workflows across Tax, Audit, Legal and Compliance. TORONTO, Nov. 5, 2025 /PRNewswire/ -- Thomson Reuters (TSX/Nasda...
11-05 22:00
Canaccord Genuity analyst Aravinda Galappatthige upgrades Thomson Reuters (NASDAQ:TRI) from Hold to Buy and lowers the price target from $182 to $174.
11-05 19:47
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Thomson Reuters业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **第三季度整体表现:** - 总公司有机营收增长7%,符合预期 - 核心三大业务板块(法律专业人士、企业客户、税务会计专业人士)有机营收增长9% - 调整后EBITDA增长10%至6.72亿美元 - 调整后每股收益从0.80美元增至0.85美元 - 前九个月自由现金流约14亿美元,同比下降3% **分业务板块表现:** - 法律专业人士:有机营收增长9%(较上半年8%有所加速) - 企业客户:有机营收增长7%,其中经常性收入增长9%,交易性收入增长5% -
11-05 12:24
Thomson Reuters shares are trading lower. The company reported Q3 financial res...
11-04 23:17